-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 30, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that the ABSK043 capsules declared by Heyu Pharmaceutical obtained the implied license for clinical trials, and the proposed indication is malignant tumors
Screenshot source: CDE official website
In the field of tumor immunotherapy, the development of small molecule PD-1/PD-L1 inhibitors has gradually attracted attention
According to an earlier press release from Heyu Medicine, ABSK043 is a new small molecule PD-L1 inhibitor with better activity and selectivity
picture
In August 2021, Heyu Pharma completed the first patient dosing in the Phase 1 clinical trial of ABSK043 in Australia
References:
[1] The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China.
[3] Heyu Pharma announced the identification of two new-generation innovative anti-tumor drug candidates, and will present a number of drug discovery and translational medicine research results at the 2022 AACR Annual Meeting.
